← Eichor
Study identifier: NCT05384392 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Biomarkers Predictive of Thymic Evolution and Therapeutic Response at 2 Years in Patients With a First Psychotic Episode

Condition: First-episode Psychosis  ·  Sponsor: University Hospital, Brest

PhaseNA
Planned participants217
Who can joinAll sexes, 15 Years to 30 Years
Healthy volunteersNo

About this study

Psychosis is a severe, common, and disabling psychological disorder. An epidemiological study conducted in England reported an incidence of 34 new cases per 100,000 person-years, with a peak between 16 and 19 years of age. Following a first psychotic episode, two clinical evolutions are possible: thymic psychosis (17%) and non thymic psychosis (83%). The first includes bipolar disorders with a psychotic component and major depressive disorders with a psychotic component; the second, other psychotic disorders, mainly schizophrenia. One of the major difficulties encountered is the frequent impossibility of specifying the type of psychosis at the beginning of the psychotic episode. However, these disorders require different therapies, particularly medication. This leads to a delay in diagnosis with a high risk of relapse. The semiological study of these diseases being carried out within the framework of interviews, it seems interesting to be able to record these and to obtain a quantitative and objective measurement through the study of language. The use of machine learning has made it possible to distinguish patients with schizophrenia from those with bipolar disorder by graphical analysis of language in a more efficient way than with clinical scales.Moreover, it is possible to identify linguistic markers: thus, an alteration of syntactic structures and prosody would be more present in non-thymic than in thymic psychoses. Paraclinical markers are also emerging. In particular,…

This description comes directly from the study's public registry record.

Talk to the study team

Florian STEPHAN  ·  2.98.34.77.34  ·  florian.stephan@chu-brest.fr

Christophe LEMEY  ·  2.98.22.38.67  ·  christophe.lemey@chu-brest.fr

Always discuss trial participation with your own doctor first.

Locations (5)

Dr Efflam BREGEONAngers, FranceRecruiting
Dr Florian STEPHANBrest, FranceRecruiting
Dr Anne SAUVAGETNantes, FranceNot Yet Recruiting
Dr Dominique DRAPIERRennes, FranceRecruiting
Dr Vincent CAMUSTours, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05384392